



## VÉTOQUINOL AND JANSSEN ANIMAL HEALTH FINALIZE AN AGREEMENT FOR THE EXCLUSIVE DISTRIBUTION OF SUROLAN® IN THE UNITED STATES

January 14, 2010 (Lure, France) – As part of its strategy of expanding its sales in the American market, Vétoquinol is pleased to announce an agreement with Janssen Animal Health to distribute Surolan® in the United States, following its approval by the FDA in December 2009. Surolan® is a leading example of Vétoquinol's strategic focus on anti-infective agents and its success in this area. Surolan® has an excellent reputation in Europe, where it has been a great success.

Surolan® combines the effects of three active ingredients – an antibiotic, an anti-fungal and an anti-inflammatory – permitting a complete treatment of otitis externa in dogs, a condition which affects as much as 20% of the canine population in the United States.

“We are very pleased with this collaboration”, stated Matthieu Frechin, Deputy General Manager of Vétoquinol, “which enables us to introduce an innovative new medication to the U.S. market. The announcement of the FDA's approval to market Surolan® in the United States has been very well received by the American veterinary profession.”

Surolan® will be launched at the next North American Veterinary Congress in Orlando, Florida, which opens on January 16.

Upcoming event: 2009 Annual revenues (Thursday, 21 January 2010)

### **About Vétoquinol**

*Vétoquinol is an independent veterinary pharmaceutical laboratory serving both the companion and production animal markets. This family-owned group specialized exclusively in animal health is the 11<sup>th</sup> largest laboratory in the world, and more than 80% of Vétoquinol's revenues come from outside France.*

*Vétoquinol engages in the research and development, production and marketing of medical and nutraceutical products. Vétoquinol has positioned itself in the curative sector, and has developed expertise in three therapeutic fields: anti-infectives, pain/inflammation, and cardiology/ nephrology.*

*The Group currently distributes its products in one hundred countries throughout Europe, North America and Asia/Pacific, with subsidiaries in 23 different countries and a network of 140 distributor partners. The Company has more than 1,550 employees worldwide.*

**For more information:** [www.vetoquinol.com](http://www.vetoquinol.com).

**OUR BUSINESS: ANIMALS. OUR ADVANTAGE: PEOPLE.**

For more information, contact:

#### **VETOQUINOL**

Finance department  
Pierre KONAREFF  
Tel: 03 84 62 59 88  
[relations.investisseurs@vetoquinol.com](mailto:relations.investisseurs@vetoquinol.com)

#### **KEIMA COMMUNICATION**

Investor relations  
Emmanuel DOVERGNE  
Tel: 01 56 43 44 63  
[emmanuel.dovergne@keima.fr](mailto:emmanuel.dovergne@keima.fr)

Media relations  
Sibylle DESCAMPS DUBOIS  
Tel: 01 56 43 44 72  
[sibylle.descamps@keima.fr](mailto:sibylle.descamps@keima.fr)